2m 2m 2m 2m 2m 2m 2m
ANBIO-A (NNNN)
NASDAQ
$15.48-$0.11 (-0.71%)
Price as of Jun 12, 2026 4:20 PM EDT- $26.3MMarket Cap
- 80.02%1-Year Change
- Medical Instruments & SuppliesIndustry
ANBIO-A (NNNN)
$15.48-$0.11 (-0.71%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | 8.6M +5.64% | 8.2M N/A | |
Cost of Revenue | 1.1M -52.01% | 2.3M N/A | |
Gross Profit | 7.5M +28.17% | 5.9M N/A | |
Sales and Marketing Expense | 1.6M -54.18% | 3.4M N/A | |
Research and Development Expense | -201,305 -55.68% | -454,227 N/A | |
Depreciation and Amortization Expense | N/A N/A | N/A N/A | |
Total Operating Expenses | 1.8M -54.36% | 3.9M N/A | |
Operating Profit | 5.8M +189.06% | 2.0M N/A | |
Interest Income | 142,023 -57.92% | 337,511 N/A | |
Interest Expense | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 142,023 -57.92% | 337,511 N/A | |
Total Nonoperating Income and Expense | 635,723 +68.41% | 377,475 N/A | |
Income before Taxes | 6.4M +169.86% | 2.4M N/A | |
Income Taxes | 0 N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | |
Net Income | 6.4M +169.86% | 2.4M N/A | |
Net Income from Continuing Operations Applicable to Common | 6.4M +169.86% | 2.4M N/A | |
Basic EPS and Net Income | 0.15 +162.50% | 0.06 N/A | |
Diluted EPS and Net Income | 0.15 +162.50% | 0.06 N/A | |
Basic Weighted Average Shares | 43.7M +3.27% | 42.3M N/A | |
Diluted Weighted Average Shares | 43.7M +3.27% | 42.3M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 7.8M -33.96% | 11.8M N/A | |
Short-Term Investments | 4.1M N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 11.9M +1.19% | 11.8M N/A | |
Total Current Assets | 30.2M +63.17% | 18.5M N/A | |
Accumulated Depreciation | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | N/A N/A | N/A N/A | |
Total Long-Term Assets | 0 -100.00% | 387,440 N/A | |
Total Assets | 30.2M +59.83% | 18.9M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | |
Total Current Liabilities | 87,836 -94.92% | 1.7M N/A | |
Total Long-Term Debt | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | N/A N/A | N/A N/A | |
Total Liabilities | 87,836 -94.92% | 1.7M N/A | |
Retained Earnings | 23.6M +37.29% | 17.2M N/A | |
Total Stockholders Equity | 30.2M +75.41% | 17.2M N/A | |
Total Shares Outstanding | 43.9M +3.78% | 42.3M N/A | |
Cash Flow | |||
Cash from Operating Activities | -6.7M -423.93% | 2.1M N/A | |
Capital Expenditures | N/A N/A | N/A N/A | |
Cash from Investing Activities | -4.2M -1,346.66% | 337,101 N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 6.9M +2,116.06% | -344,605 N/A | |
Financials Ratio | |||
Gross Margin | 87.24% N/A | N/A N/A | |
Operating Margin | 66.70% N/A | N/A N/A | |
Return on Assets | 26.05% N/A | N/A N/A | |
Return on Equity | 27.05% N/A | N/A N/A | |
Revenue Growth | 5.64% N/A | N/A N/A | |
Current Ratio | 344.31 N/A | N/A N/A | |
Cash Ratio | 88.42 N/A | N/A N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow